Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
16/11/2022
eNrdWNty2jAQfc9XMH6XzTWYjiHT0qRlJplSEqadvjBCXoOokBxdCOnXV8akJR27SUT8khfG6LK7ks45u1J0tl2z2gakooL3vYZf92rAiYgpX/S96c0FCr2zwUm0wht8MKzr1/1G06sRhpXqe1mvPwfMlf/96vIj2PkgvcFJLRLzFRD9aJzRlPmfsVpe4TQbU4s2gsa1NeiliPteavSutRYpLW0Ugzshf6oUE4iCfcth72rWPmyPgszYM6waBfIS80WhUeBONomRErgeYg0LIe8LTacybsyavfC00QudnFA1ASWMJDDGejmWYkNjiAt9JZgpcHKS3MXXIDcMdOak0HiwImvlZByv8HYCt6PioN/b3qHealRHjW6n3TrtdXphO2w4uZIHW1UMH7uIIJ21WmEnDNsB8CAGQjOUI46a9WYT1VvdThCTQMEaxQY16oiLDaznEvJ+20YEY7AAFANiGC2x0YDsj5BU7xoV5vYjFVLbDyQhMQrFCBMCCqXSsoU8zFWp9Y7Zbp5J6daiyREk48wbqwgeVA0fQ70iPxJun4RhTFXK8L2/UqnrVmGJbTdIK0jVLSRbwY20Esnsnv1jnxvGghdGPd0LWEURZ/o4FIbrEh27mLhuxFBYNmzLT9RNevV2j0UK6vXM/hK8OO2MzZxR4qqtVv0MKD2djMql9U2q0gesYCqrk6VvlMfiTr2+3B3Cq6LodyfBnigaOh1nNv+wWC7JuedGihQCK4RUHaNvI56IY5XN0qPY1AM53h4vdrWoIJhBSTWKHNXWEuKheK6MctXROe8oNPrp/MYVp18NyPvr3d9C0zTu/0GYWyqqIr9ZVpQG/nKO5VLz33tKQmbNsNsOW263FCOLlWypdareBcESq5xofiLfbro7KHWqu6hVUk/l9WWeMioKfZ7XAs+HiSvjn6q2jr1B7OfvbyqFPrQ0cMQ55MmhMgkfnb9+Vvh7fags7PEjFavOza7Ux9rKUVWVn5kXl31H5SF7rvxCWnH4kiS05PWsFJdRkL/cDU6iIHu1G5z8Br/4pO4=
784WkRBa53VPxHay